ArticleAnnals of medicine and surgery (2012)2026
Microbial metabolites from gut bacteria as novel anti-cancer agents.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Tissue-Engineered In Vitro Intestinal Wall Model for Assessing the Immunomodulatory Activity of the Human Gut Microbiota.Bulletin of experimental biology and medicine · 2026Article
- Impact of Initial Care at a Neurosurgery-Capable Facility on Mortality Among Patients with Moderate-to-Severe Traumatic Brain Injury in South Africa.Neurocritical care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence highlights the potential of gut microbial metabolites as promising anticancer agents, with mechanisms distinct from those of conventional chemotherapeutics. Short-chain fatty acids, particularly butyrate, exhibit histone deacetylase inhibitory activity, leading to apoptosis and cell-cycle arrest in colorectal and breast cancers. Reuterin, a redox-active metabolite of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.